Document Detail


Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?
MedLine Citation:
PMID:  22228288     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A best-evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'Is a fully heparin bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?' Altogether more than 792 papers were found using the reported search, of which 13 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated (Table 1). The studies analysed show that perfusion with heparin-coated and heparin-polymer-coated bypass does not increase the risk of adverse effects but reduces blood loss, re-operation rates, ventilation time, length of intensive care unit (ICU) and hospital stay and is also associated with improved biocompatibility, as evidenced by platelet preservation, reduced leucocyte and complement activation, and proinflammatory cytokine production. The various coated circuits have comparable biocompatibility as evaluated by a range of inflammatory markers and clinical outcomes. Three studies documented a significant decrease in post-operative blood loss (P = 0.001-0.54) and a meta-analysis found that perfusion with a heparin-bonded circuit resulted in a reduction in blood transfusion requirements (20%), ventilation time (P < 0.01), length of time in the ICU (P < 0.01) and also hospital stay (P = 0.02). Two studies found reduced levels of polymorphonuclear elastase (P < 0.018-0.001) and two trials concluded that the use of heparin-coated circuits in combination with low-dose systemic heparin (activated clotting time >250) resulted in the greatest clinical benefit and improvement in inflammation. One study documented significant platelet preservation with the use of third-generation heparin-polymer-bonded circuits (P ≤ 0.05). We conclude that despite heparin-bonded and newer third-generation heparin-polymer-bonded cardiopulmonary bypass circuits having a greater cost per person, their improved clinical outcomes and biocompatibility in patients undergoing cardiac surgery make them a preferable option to standard non-heparin-bonded circuits.
Authors:
Sarah Mahmood; Haris Bilal; Mahvash Zaman; Augustine Tang
Related Documents :
12768308 - Posttraumatic contracture of elbow treated with intraarticular technique.
21804138 - Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are ...
21831588 - Critical limb ischemia-need to look beyond limb salvage.
20888168 - Osteochondritis dissecans of the capitellum: minimum 1-year follow-up after arthroscopi...
12711818 - A two-year analysis of risk factors and outcome in patients with bloodstream infection.
2558888 - Wilms tumour in a patient with growth hormone replacement therapy.
Publication Detail:
Type:  Journal Article; Review     Date:  2012-01-06
Journal Detail:
Title:  Interactive cardiovascular and thoracic surgery     Volume:  14     ISSN:  1569-9285     ISO Abbreviation:  Interact Cardiovasc Thorac Surg     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-22     Completed Date:  2012-07-24     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101158399     Medline TA:  Interact Cardiovasc Thorac Surg     Country:  England    
Other Details:
Languages:  eng     Pagination:  406-14     Citation Subset:  IM    
Affiliation:
School of Medicine, University of Liverpool, Liverpool, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anticoagulants / administration & dosage*,  economics
Benchmarking
Cardiopulmonary Bypass / adverse effects,  economics,  instrumentation*
Coated Materials, Biocompatible* / economics
Cost-Benefit Analysis
Equipment Design
Evidence-Based Medicine
Female
Heparin / administration & dosage*,  economics
Hospital Costs
Humans
Length of Stay
Male
Middle Aged
Postoperative Complications / etiology,  prevention & control
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Coated Materials, Biocompatible; 9005-49-6/Heparin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Minimally invasive thoracoscopic hybrid treatment of lone atrial fibrillation: early results of mono...
Next Document:  A 15-cm aneurysm of the right coronary artery presenting as a pericardial cyst.